Zacks.com on MSN6d
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.
Life Science Leader19h
Annovis Bio: Against The Grain In Alzheimer's Disease
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...
Pharmabiz7d
Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease
The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's treatment for ...
Nasdaq6d
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...